By Sahithya K · Reviewed by Divya Chandradhara · Published 8 November 2026
Under the New Drugs and Clinical Trials Rules, 2019, the investigator must report every serious adverse event in a clinical trial to the Central Licencing Authority, the sponsor and the approving Ethics Committee within twenty-four hours of its occurrence. An analysed report follows within fourteen days. The Ethics Committee then has thirty days to give its opinion, and the Authority decides any compensation within ninety days.
Serious adverse event definition under the NDCT Rules
The NDCT Rules define a serious adverse event, in rule 2, as an untoward medical occurrence during a clinical trial that results in any of the following:
death
permanent disability
hospitalisation of the trial subject, where the subject is an outpatient or a healthy person
prolongation of hospitalisation, where the subject is an inpatient
persistent or significant disability or incapacity
congenital anomaly or birth defect
a life-threatening event
The definition turns on the outcome, not on whether the event is thought to be caused by the drug. Causality is assessed later in the process, so an event is reported as serious whether or not the investigator considers it related to the study.
The 24-hour SAE report by the investigator
The investigator must report all serious adverse events within twenty-four hours of their occurrence, under rule 42(1) and the Third Schedule. The report goes to three parties at once: the Central Licencing Authority, the sponsor or its representative who obtained the trial permission, and the Ethics Committee that approved the study protocol.
If the investigator misses the twenty-four-hour period, the Rules require the investigator to give the reasons for the delay, to the satisfaction of the Central Licencing Authority, along with the report. A late report is still a report that must be made, and the explanation becomes part of the record.
The 14-day analysed SAE report
After the first report, the sponsor and the investigator each forward a report on the serious adverse event after due analysis within fourteen days. The recipients are the Central Licencing Authority, the chairperson of the Ethics Committee and the head of the institution where the trial was conducted. The Third Schedule sets the information the report carries in its Table 5.
The starting point of the fourteen days is worded differently in different places. For deaths, rule 42(2) runs it from the knowledge of the occurrence of the event. For other injuries, rule 42(3) runs it from the reporting of the event. The Third Schedule runs the sponsor’s period from knowledge of the occurrence and the investigator’s from the occurrence. Sponsors usually plan to the earliest of these readings.
Table 1. What the analysed report must contain (Third Schedule, Table 5)
| Section | What is required |
|---|---|
| Patient details | Initials and another identifier such as a hospital or outpatient record number (mandatory), gender, age or date of birth, weight and height |
| Suspected drug | Generic name (mandatory), indication, dosage form and strength, daily dose and regimen, route, start and stop dates and times |
| Other treatments | The same details for concomitant drugs, including over-the-counter products and non-drug therapies |
| Details of the event | Full description, including body site, severity and the seriousness criterion, with a specific diagnosis where possible (mandatory); onset and stop dates; dechallenge and rechallenge information; setting |
| Outcome | Recovery and any sequelae and test results; for a fatal outcome the cause of death, its possible relationship to the event and any post-mortem findings |
| Investigator details | Name and address (mandatory), telephone, specialty, dates of reporting to the Central Licencing Authority and the Ethics Committee, signature |
Ethics committee review of an SAE within thirty days
The Ethics Committee forwards its own report on the serious adverse event, after due analysis, together with its opinion on financial compensation, within thirty days of receiving the investigator’s report. Its opinion on the amount is determined using the formula in the Seventh Schedule. For a death, the report goes to the Central Licencing Authority. For permanent disability or other injury, rule 42(3) sets the same thirty-day period for the committee’s report and opinion.
How a trial-related death is examined and compensated
For a death, the Central Licencing Authority constitutes an independent expert committee to examine the case, under rule 42(2). The Authority forwards the reports of the investigator, the sponsor and the Ethics Committee to the expert committee’s chairperson. The expert committee recommends the cause of death and, where the death is related to the trial, the quantum of compensation, within sixty days of receiving the report.
The Central Licencing Authority then decides whether the death is related to the trial and, if it is, orders the compensation within ninety days of receipt of the report of the serious adverse event. The sponsor pays within thirty days of receiving the order.
How permanent disability and other injuries are examined
For permanent disability or other injury, the Central Licencing Authority determines the cause itself, or constitutes an independent expert committee where it considers that necessary, under rule 42(3). An expert committee, if formed, makes its recommendation within sixty days. The Authority orders the compensation for a trial-related injury within ninety days of receipt of the report, and the sponsor pays within thirty days of receiving the order.
Separately from compensation, which trial subjects are told about during informed consent, the sponsor must provide free medical management for an injury for as long as the investigator considers it necessary, or until it is established that the injury is not related to the study, under rule 40. The two obligations are independent of each other.
SAE reporting timelines in India: every clock in one table
Table 2. Serious adverse event periods under the NDCT Rules
| Step | Who acts | Period | Source |
|---|---|---|---|
| First report of the event to the Authority, sponsor and Ethics Committee | Investigator | Twenty-four hours of occurrence | Rule 42(1); Third Schedule |
| Analysed report to the Authority, Ethics Committee chair and head of institution | Sponsor and investigator | Fourteen days | Rule 42(2) and (3); Third Schedule |
| Ethics Committee report with opinion on compensation | Ethics Committee | Thirty days of receiving the report | Rule 42(2) and (3) |
| Expert committee recommendation | Independent expert committee | Sixty days of receiving the report | Rule 42(2) and (3) |
| Order on cause and compensation | Central Licencing Authority | Ninety days of receipt of the report | Rule 42(2) and (3) |
| Payment of compensation | Sponsor | Thirty days of receiving the order | Rule 42(2) and (3) |
Every period in this table is stated in hours or days in the Rules, not in working days. The working-day periods elsewhere in the Rules, such as the decision periods for trial permissions, do not apply here. A team that reuses a working-day calendar for safety reporting will report late.
SAE reporting alongside ongoing trial safety reporting
Serious adverse event reporting is one part of the safety obligations a clinical trial carries. Under rule 25, the analysed report of any serious adverse event is a condition of the trial permission, alongside the six-monthly status report on each trial submitted to the Central Licencing Authority through the SUGAM portal. After approval, the same events feed the pharmacovigilance system the Fifth Schedule requires of anyone marketing a new drug, which is where post-marketing surveillance takes over.
Questions about SAE reporting in India
What is the SAE reporting timeline in India?
The investigator reports a serious adverse event within twenty-four hours of its occurrence to the Central Licencing Authority, the sponsor and the Ethics Committee. The sponsor and investigator each send an analysed report within fourteen days. The Ethics Committee gives its opinion within thirty days, and the Authority orders any compensation within ninety days.
Who must report a serious adverse event in an Indian clinical trial?
The investigator makes the first report within twenty-four hours. The sponsor, or its representative who obtained the trial permission, and the investigator each then forward an analysed report within fourteen days. The Ethics Committee that approved the protocol sends its own report and its opinion on compensation.
Are SAE timelines in working days or calendar days?
Calendar days. Rule 42 of the NDCT Rules states the serious adverse event periods in hours and days, not working days. That distinguishes them from the permission and registration periods elsewhere in the Rules, which are mostly stated in working days and are often confused with them.
Does an SAE have to be reported if it is not related to the study drug?
Yes. The definition of a serious adverse event depends on the outcome, such as death, hospitalisation or a life-threatening event, not on its cause. Relatedness is assessed afterwards by the Ethics Committee, an expert committee where one is formed and the Central Licencing Authority.
What happens if the investigator reports an SAE late?
The investigator must still report the event and must give the reasons for the delay, to the satisfaction of the Central Licencing Authority, along with the report. The Rules treat the twenty-four-hour period as a firm requirement, and the reasons for any delay become part of the record of the event.
Who decides compensation for a trial-related injury or death?
The Central Licencing Authority decides, by order, after considering the Ethics Committee’s opinion and, where one is formed, the expert committee’s recommendation. The amount is determined using the formula in the Seventh Schedule, and the sponsor pays within thirty days of receiving the order.
About this guide
This guide is based on rules 2, 25, 40 and 42 and the Third Schedule of the New Drugs and Clinical Trials Rules, 2019, in the gazette text published by the Central Drugs Standard Control Organisation. It was written by Sahithya K, and reviewed by Divya Chandradhara It states the position as at 8 November 2026 and is reviewed every six months and after any amendment to the Rules.